The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE)

This publication has 52 references indexed in Scilit:

• Palliative care research
  European Journal Of Cancer, 2001
• Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
  The Lancet, 2001
• Docetaxel + Cisplatin (DC) and Docetaxel + Carboplatin (DCb) vs Vinorelbine + Cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer (NSCLC): Results of a multicenter, randomized phase III study
  European Journal Of Cancer, 2001
• Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness
  European Journal Of Cancer, 2001
• Long Term Analysis of Survival in the European Randomized Trial Comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine Alone in Advanced Non-Small Cell Lung Cancer
  The Oncologist, 2001
• Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer A multicenter phase II study
  Lung Cancer, 2000
• Variation in survival of patients with lung cancer in Europe, 1985–1989
  European Journal Of Cancer, 1998
• 243 Spanish lung cancer group randomized trial of preoperative chemotherapy (cisplatin either 50 mg/m2 or 100 mg/m2) in stage IIIA (N2) non-small cell lung cancer (NSCLC)
  Lung Cancer, 1997
• The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
  European Journal Of Cancer, 1996
• A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group
  Cancer Chemotherapy and Pharmacology, 1990